The European Bank for Reconstruction and Development (EBRD) will support the development of Uzbekistan's pharmaceutical industry by providing Nika Pharm with a loan of up to $20 million. The funds will be used for balance sheet restructuring, modernization of equipment and production facilities, which will make it possible to increase output and bring production into compliance with the World Health Organization's GMP standards.
Nika Pharm manufactures tablets, capsules, sachets, and nasal sprays for the treatment of colds, as well as medicines in the fields of gastroenterology, pediatrics, and urology. The company has already established itself as a reliable manufacturer and replaces imports with high-quality domestic products, holding leading positions in a number of segments, including decongestants.
The project will make it possible to increase the output of generics and prescription medicines by 140%, expand the production base, and improve the company's operational efficiency. Combined with GMP certification, this will strengthen Nika Pharm's position in the domestic market and in the region, and will also support the state strategy of raising the share of locally manufactured pharmaceuticals to 80%.
